Physician

Paul David Zito, MBBS

According to 2025 Medicare claims, Paul Zito, MBBS (NPI: 1396155966) practices hematology/oncology in the Tulsa, OK market, with the plurality of this provider's patient population coming from Tulsa, OK. This provider's primary affiliated billing organization is OKLAHOMA CANCER SPECIALISTS AND RESEARCH INSTITUTE LLC (NPI: 1962876045; TIN: 383983999) and primary practice location at 74146-6236. Zito is affiliated with the Caravan Health ACO 50 LLC (ACO ID: A5160) and Sound Physicians Long Term Care Management, LLC (ACO ID: A5220), participating under the MSSP model.

Zito's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 997 traditional Medicare patients, billed 200,019 HCPCS/CPT codes, and received $3,413,986 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 2,374 prescription claims across 351 beneficiaries totaling $4,259,721 in drug costs, led by Ibrance (Palbociclib). 2023 DME data shows 14 claims. Open Payments data shows 31 records totaling $4,997. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $11,938 to $3,413,986. Similarly, Part D prescription costs have moved sharply higher in recent years, from $2,107 to $4,259,721. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	66	113	$11,938
2018	89	108	$12,425
2019	50	60	$7,617
2020	127	234	$20,213
2021	395	47,075	$830,675
2022	931	199,873	$3,400,493
2023	986	217,179	$3,375,991
2024	997	200,019	$3,413,986

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	21	93	$2,107
2016	26	93	$10,444
2017	36	127	$10,936
2018	41	113	$62,919
2019	69	309	$382,318
2020	80	443	$552,879
2021	105	498	$352,885
2022	221	1,336	$1,385,146
2023	281	1,762	$2,301,373
2024	351	2,374	$4,259,721

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	55	$1,365
2023	N/R	14	$7,644
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	274	447	$88
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	276	793	$86
80053	Blood test, comprehensive group of blood chemicals	260	1,241	$10
36415	Insertion of needle into vein for collection of blood sample	260	834	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	271	1,263	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	42	1,176	$634,367
Revlimid	Lenalidomide	35	826	$476,806
Inlyta	Axitinib	19	570	$335,088
Tagrisso	Osimertinib Mesylate	21	622	$334,221
Vonjo	Pacritinib Citrate	13	390	$327,048

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	30	$829	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$4,167	Mirati Therapeutics, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Paul David Zito, MBBS?

Tedicare shows public-source Medicare data for Paul David Zito, MBBS (NPI 1396155966), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Paul David Zito, MBBS have ACO affiliation data?

Paul David Zito, MBBS is shown with ACO affiliation data for Caravan Health ACO 50 LLC (MSSP, ACO ID A5160) and Sound Physicians Long Term Care Management, LLC (MSSP, ACO ID A5220).

What billing organization is linked to Paul David Zito, MBBS?

Paul David Zito, MBBS is linked to OKLAHOMA CANCER SPECIALISTS AND RESEARCH INSTITUTE LLC (billing NPI 1962876045) in the available physician profile data.

Does Paul David Zito, MBBS have Open Payments data?

Paul David Zito, MBBS has 31 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.